BaseSpace
Import Your Data
QuickView

FAQ

More QuickView FAQs

Back to top
Clear Search sequence regions
(e.g. HIV infection, Endothelial cell, Pharmacogenetics, Cisplatin, rs7903146, EGFR)
Bookmark Forward

QuickView for CD96 (gene)


Body Atlas

Most Correlated Tissues

  1. Natural killer cell of peripheral blood
  2. T Lymphocyte (CD8+) of peripheral blood
  3. T Lymphocyte (CD4+) of peripheral blood
  4. T Lymphocyte (regulatory) of peripheral blood
  5. Mononuclear cell of peripheral blood
Explore Body Atlas Results

Disease Atlas

Most Correlated Diseases

  1. Viremia
  2. Craniosynostosis syndrome
  3. Sepsis due to Escherichia coli
  4. Sepsis due to coagulase negative Staphylococcus
  5. Disease due to Enterovirus
Explore Disease Atlas Results

Pharmaco Atlas

Most Correlated Compounds

  1. gp50 protein, Schistosoma
  2. p40 egg antigen, Schistosoma
  3. dabrafenib
  4. IGF2 protein, human
  5. Transforming Growth Factor beta1
Explore Pharmaco Atlas Results

Knockdown Atlas

Most Correlated Gene Perturbations

  1. NOL4L
  2. CD276
  3. NR4A2
  4. MBNL1
  5. TAF1
Explore Knockdown Atlas Results

Curated Studies

Most Correlated Studies

Loading...
Explore Curated Studies Results

Literature

Most Relevant Literature

  1. Hitting the complexity of the TIGIT-CD96-CD112R-CD226 axis for next-generation cancer immunotherapy.
  2. CD96, a new immune checkpoint, correlates with immune profile and clinical outcome of glioma.
  3. Interaction between nectin-1 and the human natural killer cell receptor CD96.
  4. BCL9 regulates CD226 and CD96 checkpoints in CD8+ T cells to improve PD-1 response in cancer.
  5. Prognostic impact of enhanced CD96 expression on NK cells by TGF-β1 in AML.
Explore Literature Results

Clinical Trials

Most Relevant Clinical Trials

  1. COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
  2. A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK127 in Combination Wit…
  3. First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
  4. Characterization of NK Cells Under First Line Advanced Therapy Either as Curative Therapy for Metast…
  5. A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanc…
Explore Clinical Trials Results
  • Copyright © 2024 Illumina Inc. All rights reserved.